Aclaris Therapeutics Inc
(NAS:ACRS)
$
1.185
0 (0%)
Market Cap: 84.54 Mil
Enterprise Value: -34.14 Mil
PE Ratio: 0
PB Ratio: 0.63
GF Score: 58/100 Aclaris Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 11:40PM GMT
Release Date Price:
$9.53
(+0.74%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP
Awesome. Well, thanks so much, everyone, for joining us here for the last session of the day, and thanks to the team from Aclaris. Maybe I'll turn it over to you guys to introduce yourself and give us a brief overview of the company.
Douglas J. Manion
Aclaris Therapeutics, Inc. - CEO, President & Director
Great. Let's start with Kevin.
Kevin Balthaser
Aclaris Therapeutics, Inc. - CFO
Yes. Kevin Balthaser, CFO. I've been into Aclaris now for 6 years. The first 5 of that predominantly spent running finance accounting operations for our former CFO, and I took over for him in January.
Joseph Monahan;Douglas J. Manion
Aclaris Therapeutics, Inc. - Chief Scientific Officer;Aclaris Therapeutics, Inc. - CEO, President &
And Joe Monahan, CSO of the company. Started with Aclaris in 2017 when they bought the company that I started back in 2010 called Confluence Life Sciences.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsā 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot